Forskolin

Adenylate cyclase activator



BML-CN100-0010	10 mg	101.00 USD

BML-CN100-0100	100 mg	619.00 USD

Replaces Prod. #: ALX-350-001

Activates adenylate cyclase by directly interacting with the catalytic unit of the enzyme leading to an increase in the intracellular concentration of cAMP. Widely used tool for the investigation of the role of cAMP as a second messenger with a broad range of potential therapeutic applications. Inotropic agent and vasodilator. Induces platelet aggregation. Inhibits ion channels by a mechanism that does not involve cAMP. Non-competitive inhibitor of nicotinic acetylcholine receptors. A negative control compound, 1,9-Dideoxyforskolin, is also available (Prod. No. BML-CN104).

Product Specification

Alternative Name:	Colforsin

Formula:	C₂₂H₃₄O₇

MW:	410.5

Purity:	≥99% (TLC)

Appearance:	White solid.

CAS:	66575-29-9

MI:	14: 2476

Source/Host:	Isolated from Coleus forskohlii.

Solubility:	Soluble in ethyl acetate (10mg/ml), anhydrous DMSO (5mg/ml) or 100% ethanol (6mg/ml). DMSO is the recommended solvent for activation of cAMP.

Long Term Storage:	-20°C

Use/Stability:	Stock solutions in DMSO are stable for up to 4 months when stored at +4°C. Do not dissolve in ethanol, which inhibits forskolin activation of adenylate cyclase.

Hazard:	IRRITANT.

Background / Technical Information:	Please click here for the comprehensive product data sheet.

Please mouse over

Product Literature References

Effect of forskolin on the expression of claudin-5 in human trophoblast BeWo cells: M. Harada, et al.; Pharmazie 62, 291 (2007), Abstract;

Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling: P.A. Insel & R.S. Ostrom; Cell Mol. Neurobiol. 23, 305 (2003), Review, Abstract;

The effect of forskolin on blood flow, platelet metabolism, aggregation and ATP release: J.T. Christenson, et al.; Vasa 24, 56 (1995), Abstract;

Forskolin acts as a noncompetitive inhibitor of nicotinic acetylcholine receptors: M.L. Aylwin & M.M. White; Mol. Pharmacol. 41, 908 (1992), Abstract;

Effect of forskolin on cytosolic Ca++ level and contraction in vascular smooth muscle: A. Abe & H. Karaki; J. Pharmacol. Exp. Ther. 249, 895 (1989), Abstract;

Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action?: A. Laurenza, et al.; Trends Pharmacol. Sci. 10, 442 (1989), Review, Abstract;

Forskolin: its biological and chemical properties: K.B. Seamon & J.W. Daly; Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 1 (1986), Abstract;

Use of forskolin to study the relationship between cyclic AMP formation and bone resorption in vitro: U.H. Lerner, et al.; Biochem J. 240, 529 (1986), Abstract;

Forskolin and antidiuretic hormone stimulate a Ca2+-activated K+ channel in cultured kidney cells: S.E. Guggino, et al.; Am. J. Physiol. 249, F448 (1985), Abstract;

Pharmacology and inotropic potential of forskolin in the human heart: M.R. Bristow, et al.; J. Clin. Invest. 74, 212 (1984), Abstract;

Forskolin, an activator of adenylate cyclase, increases CA2+-dependent electrical activity induced by glucose in mouse pancreatic B cells: J.C. Henquin, et al.; Endocrinology 112, 2218 (1983), Abstract;

Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties: N.J. de Souza, et al.; Med. Res. Rev. 3, 201 (1983), Abstract;

Forskolin: a unique diterpene activator of cyclic AMP-generating systems: K.B. Seamon & J.W. Daly; J. Cyclic Nucleotide Res. 7, 201 (1981), Review, Abstract;